The Phospho-c-Met (Tyr1349) antibody detects the activated form of the c-Met receptor tyrosine kinase, specifically phosphorylated at tyrosine residue 1349. c-Met, encoded by the *MET* proto-oncogene, is a transmembrane receptor for hepatocyte growth factor (HGF). Upon HGF binding, c-Met undergoes autophosphorylation at key tyrosine residues (including Tyr1349 in the cytoplasmic domain), triggering downstream signaling cascades (e.g., Ras/MAPK, PI3K/Akt) that regulate cell proliferation, survival, motility, and morphogenesis.
Tyr1349 phosphorylation is critical for recruiting adaptor proteins like Gab1. which mediate scaffold formation for signal amplification. Dysregulated c-Met signaling—due to mutations, gene amplification, or overexpression—is implicated in tumorigenesis, metastasis, and therapeutic resistance in cancers (e.g., lung, gastric, liver). The Phospho-c-Met (Tyr1349) antibody is widely used in research to assess c-Met activation status, evaluate targeted therapies (e.g., inhibitors like crizotinib or cabozantinib), and explore mechanisms of drug resistance.
This antibody is validated for applications such as Western blotting, immunohistochemistry, and immunofluorescence. Specificity for phosphorylated Tyr1349 is essential, as non-phosphorylated c-Met or off-target phosphorylation events could confound results. Proper sample handling (e.g., phosphatase inhibitors) is required to preserve phosphorylation states during experimental workflows.